Adage Capital Partners
JNCE

Adage Capital Partners’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Adage Capital Partners’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,456,023
Closed -$18.2M – 1129
2021
Q3 		$18.2M Buy
2,456,023
+28,000
+1% +$173K 0.04% 489
2021
Q2 		$16.5M Hold
2,428,023
– – 0.03% 542
2021
Q1 		$24.9M Buy
2,428,023
+956,023
+65% +$10.5M 0.05% 375
2020
Q4 		$10.3M Buy
1,472,000
+1,368,624
+1,324% +$10.7M 0.02% 583
2020
Q3 		$844K Buy
+103,376
New +$641K ﹤0.01% 728

Other funds holding JNCE

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Adage Capital Partners's JNCE Position: Q4 2021 in Review

Adage Capital Partners sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2021, closing a stake of 2,456,023 shares — an estimated $18.2M sold.

Adage Capital Partners first reported a position in JNCE in Q3 2020 and held it in 5 quarters. The position peaked at $24.9M in Q1 2021. 124 funds tracked by Wall St. Rank hold JNCE as of Q4 2021.

  • Adage Capital Partners reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Adage Capital Partners sold 2,456,023 Jounce Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $18.2M.
  • Adage Capital Partners first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2020 and held it in 5 quarters.
  • Adage Capital Partners's Jounce Therapeutics, Inc. Common Stock position peaked at $24.9M in Q1 2021.
  • 124 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Adage Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.